Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 1,810,000 shares, an increase of 83.2% from the April 30th total of 988,200 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 1.3 days.
Institutional Trading of Cellebrite DI
A number of hedge funds have recently bought and sold shares of CLBT. Axon Enterprise Inc. bought a new stake in Cellebrite DI in the 4th quarter worth approximately $198,270,000. FMR LLC lifted its position in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after buying an additional 5,004,587 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Cellebrite DI in the 1st quarter worth approximately $60,939,000. True Wind Capital Management L.P. lifted its position in Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after buying an additional 2,130,386 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Cellebrite DI by 122.1% in the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after buying an additional 1,811,757 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on CLBT. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Needham & Company LLC reduced their target price on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Finally, Lake Street Capital lifted their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $22.43.
Read Our Latest Analysis on CLBT
Cellebrite DI Trading Down 2.0%
Shares of CLBT traded down $0.33 during trading hours on Monday, reaching $16.35. 1,512,795 shares of the company's stock traded hands, compared to its average volume of 1,462,412. The stock has a market cap of $3.92 billion, a PE ratio of -11.76, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The firm's 50 day simple moving average is $18.65 and its 200-day simple moving average is $20.15. Cellebrite DI has a 12 month low of $10.25 and a 12 month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company's revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter last year, the company posted $0.08 EPS. As a group, analysts expect that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
